Synergistic anti-leukemic interactions between ABT-199 and panobinostat in acute myeloid leukemia ex vivo

Jonathan Schwartz1, Xiaojia Niu2, Eric Walton3, Laura Hurley4, Hai Lin5, Holly Edwards7,8, Jeffrey W Taub1,6, Zhihong Wang1,6, Yubin Ge6,7,8

1Division of Pediatric Hematology/Oncology, Children’s Hospital of Michigan, Detroit, MI, USA; 2National Engineering Laboratory for AIDS Vaccine, Key Laboratory for Molecular Enzymology & Engineering, The Ministry of Education, School of Life Sciences, Jilin University, Changchun, China; 3MD/PhD Program, 4Cancer Biology Graduate Program, 5Departments of Pediatrics, 6Oncology, School of Medicine, Wayne State University, Detroit, MI, USA; 7Department of Hematology and Oncology, The First Hospital of Jilin University, Changchun, China; 8Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, School of Medicine, Wayne State University, Detroit, MI, USA

Received March 22, 2016; Accepted July 11, 2016; Epub September 15, 2016; Published September 30, 2016

Abstract: Cure rates for acute myeloid leukemia (AML) remain suboptimal; thus new treatment strategies are needed for this deadly disease. Poor clinical outcomes have been associated with overexpression of the anti-apoptotic Bcl-2 family proteins Bcl-2, Bcl-xL, and Mcl-1, which have garnered great interest as therapeutic targets. While the Bcl-2-selective inhibitor ABT-199 has demonstrated promising preclinical anti-leukemic activities, intrinsic drug resistance remains a problem. In our most recent study, we identified Mcl-1 sequestration of Bim as a mechanism of intrinsic resistance to ABT-199 in AML cells, thus upregulating Bim could overcome such resistance. Histone deacetylase (HDAC) inhibitors (HDACI) are a class of agents that have been confirmed to upregulate Bim. This prompted our hypothesis that combining an HDACI with ABT-199 would overcome intrinsic resistance to ABT-199 and result in synergistic anti-leukemic activity against AML. In this study, we investigated the anti-leukemic activity of panobinostat, a pan-HDACI, in combination with ABT-199 in AML cell lines and primary patient samples. We found that the combined drug treatment resulted in synergistic induction of cell death in both AML cell lines and primary patient samples. Panobinostat treatment resulted in upregulation of Bim, which remained elevated in the presence of ABT-199. In addition, shRNA knockdown of Bim in AML cell lines significantly attenuated apoptosis induced by combined panobinostat and ABT-199. Our results provide compelling evidence that Bim plays a key role in the combined anti-leukemic activity of panobinostat and ABT-199 against AML, and support clinical evaluation of combined panobinostat and ABT-199 in the treatment of AML.

Keywords: ABT-199, Bcl-2, Bim, panobinostat, acute myeloid leukemia

Introduction

The five year survival rate for adults with acute myeloid leukemia (AML) is a dismal 25% [1]. Although the survival rate for the pediatric population is 65%, this significantly lags behind the overall survival rate for pediatric acute lymphoblastic leukemia (approximately 90%) [1]. Resistance to chemotherapy in leukemic cell line models and poor clinical outcomes of adult patients with AML have been associated with overexpression of the anti-apoptotic Bcl-2 family proteins Bcl-2, Bcl-xL, and Mcl-1, which have garnered great interest as potential therapeutic targets [2]. Inhibitors targeting multiple anti-apoptotic Bcl-2 family proteins have shown great potential in preclinical models but have limited clinical applicability due to increased incidence of thrombocytopenia; which was associated with inhibition of Bcl-xL [2]. Thus, attention has shifted to the Bcl-2-selective inhibitor ABT-199 (Venetoclax), which has shown excellent anti-leukemic activity against chronic lymphoclastic leukemia [3] and was approved by the US FDA in April 2016. Although ABT-199 has been shown to have promising preclinical effects on AML, intrinsic drug resistance remains a concern [4-6].

Mcl-1 has been identified as playing a key role in resistance to ABT-199 in AML and lymphoid malignancies [5, 7, 8]. In our most recent study,
ABT-199 synergizes with Panobinostat in AML

ABT-199 treatment was found to result in dissociation of pro-apoptotic Bim from Bcl-2, demonstrating its canonical role in inducing apoptosis in AML cells [5]. However, ABT-199 treatment also resulted in increased sequestration of Bim by Mcl-1, preventing Bim from inducing apoptosis, while also resulting in increased Mcl-1 protein levels in ABT-199-resistant AML cells. These results suggest that Mcl-1 is a key player in the intrinsic resistance to ABT-199 in AML cells. CRISPR knockdown of Mcl-1 significantly enhanced ABT-199-induced apoptosis in AML cells, confirming its role in this aspect [5]. While there have been a number of reports focused on downregulating Mcl-1 [6, 8, 9], another approach to overcome this mechanism of intrinsic resistance to ABT-199 would be to increase Bim levels, leading to increased Bim/Mcl-1 ratio favoring apoptosis. Histone deacetylase (HDAC) inhibitors (HDACI) are a class of agents that have been demonstrated to upregulate Bim [10-12]. In particular, panobinostat, a highly potent pan-HDACI [13], has recently been approved by the US FDA for the treatment of multiple myeloma [14] and has been demonstrated to upregulate Bim in cancer cells [10, 12]. Therefore, panobinostat may overcome intrinsic ABT-199 resistance by increasing Bim protein levels. In this study, we investigated the combination of panobinostat and ABT-199 in AML cell lines and primary patient samples. We found synergistic induction of cell death by the combined drug treatment. In addition, we provided evidence that Bim played a key role in the combined anti-leukemic activity against AML. These findings support clinical evaluation of combined panobinostat and ABT-199 in the treatment of AML.

Materials and methods

Drugs

ABT-199 and panobinostat were purchased from Selleck Chemicals (Houston, TX, USA).

Cell culture

THP-1 and U937 cell lines were purchased from the American Type Culture Collection (Manassas, VA, USA). The cell lines were cultured in RPMI 1640 media with 10% fetal bovine serum (Life Technologies, Carlsbad, CA, USA) and 2 mM L-glutamine, plus 100 U/ml penicillin and 100 µg/ml streptomycin, in a 37°C humidified atmosphere containing 5% CO₂/95% air. The cell lines were tested for the presence of mycoplasma on a monthly basis.

Diagnostic blast samples were purified by standard Ficoll-Hypaque density centrifugation, then cultured in RPMI 1640 with 20% fetal bovine serum (Life Technologies, Carlsbad, CA, USA) and 2 mM L-glutamine, plus 100 U/ml penicillin and 100 µg/ml streptomycin, in a 37°C humidified atmosphere containing 5% CO₂/95% air. The cell lines were tested for the presence of mycoplasma on a monthly basis.

Clinical samples

Diagnostic AML blast samples were obtained from the First Hospital of Jilin University, Changchun, China. Written informed consent
ABT-199 synergizes with Panobinostat in AML

was provided according to the Declaration of Helsinki. Clinical samples were screened for gene mutations and fusion genes as previously described [5-7, 16, 17]. Patient characteristics are presented in Table 1.

In vitro cytotoxicity assays

In vitro cytotoxicities of the diagnostic AML blast samples were measured by using MTT (3-[4,5-dimethyl-thiazol-2-yl]-2,5-diphenyltetrazoliumbromide, Sigma-Aldrich) assays, as previously described [18, 19]. Briefly, the cells were either treated with variable concentrations of ABT-199 or panobinostat alone, or in combination, for 72 hours. The cells were lysed using 10% SDS in 10 mM HCL. IC_{50} values were calculated as drug concentrations necessary to inhibit 50% proliferation compared to vehicle control treated cells. The IC_{50} values are means of duplicates from one experiment due to limited sample. Standard isobologram analysis was performed to determine the extent and direction of anti-leukemic interactions [20]. The IC_{50} values of each drug are plotted on the axes; the solid line represents the additive effect, whereas the points represent the concentrations of each drug resulting in 50% inhibition of proliferation. Points falling below the line indicate synergistic effect, whereas those above the line indicate antagonistic effect. Patient sample selection was merely based on sample availability.

Western blot analysis

Cells were lysed in Tris buffer (10 mM, pH 8.0) containing protease inhibitors (Roche Diagnostics, Indianapolis, IN, USA). Whole cell lysates were subjected to SDS-polyacrylamide gel elec-
ABT-199 synergizes with Panobinostat in AML

Figure 2. Synergistic induction of apoptosis by ABT-199 and panobinostat in primary AML patient samples determined by annexin V/PI staining and flow cytometry and CompuSyn software analyses. Primary AML patient samples, AML#31 (A) and AML#38 (B) were treated as indicated for 24 h and then subjected to annexin V/PI staining and flow cytometry analyses. CI values were calculated using CompuSyn software. *** indicates P<0.001.

Apoptosis

AML cells were treated with variable concentrations of ABT-199 or panobinostat, alone or in combination, for 24 h, and then subjected to flow cytometry analysis to determine drug-induced apoptosis using the Annexin V-fluorescein isothiocyanate (FITC)/Propidium Iodide (PI) Apoptosis Kit (Beckman Coulter; Brea, CA, USA), as previously described [18, 23]. Results were expressed as percent of Annexin V+ cells. AML cell line experiments were performed once in triplicate due to limited sample availability. The combination index (CI) values were determined using CompuSyn software. CI<0.9 indicates synergistic, 0.9<CI<1.1 indicates additive, and CI>1.1 indicates antagonistic anti-leukemic interactions [24].

Production of lentivirus particles and transduction of AML cells

The pMD-VSV-G and delta 8.2 plasmids were gifts from Dr. Dong at Tulane University. Bim and non-target control (NTC) shRNA lentiviral vectors were purchased from Sigma-Aldrich. Lentivirus production and transduction were carried out as previously described [25, 26]. Briefly, TLA-HEK293T cells were transfected with pMD-VSV-G, delta 8.2, and lentiviral shRNA constructs using Lipofectamine and Plus reagents (Life Technologies) according to the manufacturer’s instructions. Virus containing culture medium was harvested 48 h post-transfection. Cells were transduced overnight using 1 mL of virus supernatant and 4 μg of polybrene and then cultured for an additional 48 h prior to selection with puromycin.

Statistical analysis

Differences in cell apoptosis between treated (individually or combined) and untreated cells were compared using the pair-wise two-sample
ABT-199 synergizes with Panobinostat in AML

Figure 3. Panobinostat synergizes with ABT-199 in primary patient samples determined by MTT assays and standard isobologram analyses. Primary AML patient samples were treated with ABT-199 and panobinostat, alone or in combination, for 72 h and then viable cells were determined using MTT reagent. The IC$_{50}$ values are means of duplicates from one experiment due to limited sample. Standard isobologram analysis was performed to determine the extent and direction of the anti-leukemic interaction between the two agents. The IC$_{50}$ values of each drug are plotted on the axes; the solid line represents the additive effect, while the points represent the concentrations of each drug resulting in 50% inhibition of proliferation. Points falling below the line indicate synergistic effect, whereas those above the line indicate antagonistic effect.
ABT-199 synergizes with Panobinostat in AML

**Results**

**ABT-199 and panobinostat synergize in inducing apoptosis in AML cell lines and primary patient samples**

To determine if panobinostat enhances ABT-199-induced apoptosis in AML cells, we treated two ABT-199-resistant AML cell lines, THP-1 and U937, (ABT-199 IC$_{50}$s of 2.4 mM for THP-1 and 13.5 mM for U937 cells, as determined previously by MTT assays [7]), with both drugs individually or simultaneously for 24 h. Annexin V/PI staining and flow cytometry analyses revealed significantly increased annexin V+ cells for the combined drug treatments compared to that for the individual drug treatments (Figure 1A, 1B). This was accompanied by increased cleavage of caspase-3 and PARP in the combined treatments as compared to the individual drug treatments (Figure 1C, 1D). These results demonstrate that the combined drug treatments caused significantly increased apoptosis in the two AML cell lines as compared to the individual drug treatments. Calculation of CI values by using the CompuSyn software showed that the anti-leukemic interactions between the two drugs were synergistic, as indicated by CI<0.9 (Figure 1A, 1B).

To confirm that ABT-199 and panobinostat also synergize in primary AML patient samples, we tested the drugs in two freshly isolated AML blast samples (AML#31 and AML#38; samples were chosen based on availability of adequate number of cells for the assay) ex vivo. Interestingly, simultaneous combination of the two drugs caused strong synergistic induction of apoptosis in the two primary AML patient samples, as indicated by CI<0.25 (Figure 2).

**ABT-199 and panobinostat synergize in inhibiting cell proliferation in primary AML patient samples**

To confirm the synergistic anti-leukemic interactions between ABT-199 and panobinostat in AML cells detected by annexin V/PI staining and flow cytometry analyses, MTT assays and standard isobologram analyses were performed in the AML#31 and AML#38 primary patient samples. As shown in Figure 3, simultaneous combination of the two drugs resulted in synergistic proliferation inhibition in the two primary patient samples.

To further enhance the clinical relevance of our study, we included 10 additional primary AML
ABT-199 synergizes with Panobinostat in AML

Due to limited sample availability, these additional 10 primary AML patient samples were tested by MTT assays and standard isobologram analyses, but not by annexin V/PI staining and flow cytometry analyses, which require large number of cells. Essentially the same results were obtained in the 10 additional samples as those in the AML#31 and AML#38 samples (Figure 3). These results further confirm the synergistic anti-leukemic interactions between ABT-199 and panobinostat in AML cells and the clinical relevance of our study.

Panobinostat upregulates Bim expression in AML cell lines

To determine the effects of panobinostat on Bim expression in the absence or presence of ABT-199 in AML cells, the THP-1 and U937 AML cell lines were treated with panobinostat and ABT-199, alone or in combination, for 24 h and then whole cell lysates were subjected to western blotting. The fold changes for the Bim densitometry measurements, normalized to β-actin and then compared to no drug treatment control, are indicated. (C and D) THP-1/NTC, THP-1/Bim (C), U937/NTC and U937/Bim (D) cells were treated with ABT-199 and panobinostat, alone or in combination, for 24 h and then subjected to annexin V/PI staining and flow cytometry analyses. ** indicates P<0.01 and *** indicates P<0.001.

Figure 5. The role of Bim in apoptosis induced by ABT-199 and panobinostat, alone or in combination, in AML cell lines. (A and B) THP-1 (A) and U937 (B) cells were infected with non-target control (NTC) or Bim shRNA lentivirus particles overnight, then washed and incubated for 48 h prior to adding puromycin to the culture medium. The cells were then treated with ABT-199 and panobinostat, alone or in combination, for 24 h. Whole cell lysates were subjected to Western blotting. The fold changes for the Bim densitometry measurements, normalized to β-actin and then compared to no drug treatment control, are indicated. (C and D) THP-1/NTC, THP-1/Bim (C), U937/NTC and U937/Bim (D) cells were treated with ABT-199 and panobinostat, alone or in combination, for 24 h and then subjected to annexin V/PI staining and flow cytometry analyses. ** indicates P<0.01 and *** indicates P<0.001.
ABT-199 synergizes with Panobinostat in AML

**Discussion**

In this study, we investigated the ability of panobinostat to overcome ABT-199 resistance in AML cells. We found that panobinostat synergistically enhanced ABT-199-induced apoptosis in two AML cell lines and two primary patient samples, which were relatively resistant to ABT-199. These results were further confirmed in 10 additional primary AML patient samples, as determined by MTT assays and standard isobologram analyses. Our results were similar to those of Chen et al. who used ABT-737, a Bcl-2 and Bcl-xL inhibitor, in combination with the HDACI suberoyl bis-hydroxamic acid (SBHA) and found that upregulation of Bim by SBHA contributed to the synergistic induction of cell death [11]. Another study, in mantle cell lymphoma, also found synergistic anti-cancer activity for ABT-263, which inhibits both Bcl-2 and Bcl-xL, in combination with suberoylanilide hydroxamic acid (SAHA) [27].

Consistent with other studies reporting Bim upregulation following HDACI treatment [11, 27] we confirmed that panobinostat treatment caused upregulation of Bim (30-40%) in AML cell lines. Our shRNA knockdown experiments convincingly revealed that Bim was a critical mediator of panobinostat enhancement on ABT-199-induced apoptosis. Although we did not investigate how panobinostat induces Bim expression, SAHA has been demonstrated to induce acetylation of the Bim, Bmf and NOXA promoters [27], and E2F1 has been shown to increase Bim expression following HDACI treatment [28], suggesting that increased transcription may be responsible for the upregulation of Bim by panobinostat.

However, it is important to note that although expression of the Bim shRNA in AML cell lines completely abolished Bim induction by panobinostat, it did not completely abolish drug-induced apoptosis suggesting that other factors contributed. Panobinostat has been demonstrated to affect numerous proteins which could also contribute to the enhanced cell death induced by ABT-199 [29].

In conclusion, we provide compelling evidence to support the development of panobinostat in combination with ABT-199 in the treatment of AML. Our cell line data demonstrates that ABT-199 synergizes with panobinostat in ABT-199 resistant cells. Furthermore, our MTT data using primary patient samples demonstrates that the combination also synergized in ABT-199 sensitive samples, suggesting that screening for ABT-199 resistance may not be necessary.

**Acknowledgements**

This study was supported by the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine and Jilin University, Changchun, China, grants from the Children’s Hospital of Michigan Foundation, Hyundai Hope On Wheels, the Natural Science Foundation of China (NSFC 31271477 and NSFC 31471295), the Graduate Innovation Fund of Jilin University (NX), the Christoph A.L.L. Star Foundation, and the Ring Screw Textron Endowed Chair for Pediatric Cancer Research. The funders had no role in study design, data collection, analysis and interpretation of data, decision to publish, or preparation of the manuscript.

**Disclosure of conflict of interest**

None.

**Address correspondence to:** Dr. Yubin Ge, Department of Oncology, Wayne State University School of Medicine, 110 East Warren Ave., Detroit, Michigan 48201, USA. Tel: 313-578-4285; Fax: 313-578-4287; E-mail: gey@karmanos.org; Dr. Zhihong Wang,
ABT-199 synergizes with Panobinostat in AML

References


ABT-199 synergizes with Panobinostat in AML


